The 4th Annual Gene Therapy for Rare Disorders will focus exclusively on overcoming the late-stage commercial challenges drug developers face when delivering gene therapies to market. With investment at an all-time high, […]

Recent clinical advancements of KRAS G12C inhibitors have generated increased interest in the fight to bring an end to RAS driven cancers. However, their specificity to only target G12C mutations, […]

The 9th Neurodegenerative Drug Development Summit is the industry’s definitive and unrivalled forum focused on revealing hot and promising pockets of innovation in drug discovery for neurodegenerative diseases and combating […]